GAITHERSBURG, Md.--(BUSINESS WIRE)--GenVec, Inc. (Nasdaq: GNVC) announced today that updated preliminary safety and efficacy data from the clinical development program of its lead product TNFerade™ was presented in a poster session on gastrointestinal cancers at the annual meeting of American Society for Clinical Oncology in Chicago, IL by Dr. Mitchell Posner, of the University of Chicago. An oral discussion of the posters then concluded the Saturday morning viewing session.
